Helixon US Inc. is a biotech company specializing in antibody design and is located in the Biotechnology industry. The company was founded in 2021 and recently received a significant Series A investment of CNY500.00M on 22 June 2022. The investors in this round included Gaorong Capital, Xiang He Capital, Hillhouse Investment, Neumann Advisors, Wuyuan Capital, and Qingzhi Capital. This funding signifies a strong vote of confidence in Helixon's innovative approach to antibody design and suggests promising prospects for its future growth and development in the biotechnology sector.
